Comparative Pharmacology
Head-to-head clinical analysis: FLONASE versus TRIESENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLONASE versus TRIESENCE.
FLONASE vs TRIESENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as cytokines, leukotrienes, and prostaglandins, thereby reducing nasal inflammation.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
2 sprays (50 mcg/spray) per nostril once daily; may increase to 2 sprays per nostril twice daily if needed. Intranasal route.
1 to 4 mg (0.025 to 0.1 mL of 40 mg/mL suspension) intravitreal injection once.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours (range 2-4 hours). This short half-life supports twice-daily dosing for systemic effects; however, intranasal administration achieves local therapeutic concentrations with minimal systemic exposure.
Approximately 3.3 hours for triamcinolone acetonide; with intravitreal administration, detectable levels persist for weeks to months.
Primarily hepatic metabolism (CYP3A4), with metabolites excreted in feces (approximately 87-90%) and urine (<5% unchanged). Less than 5% of a dose is excreted renally as unchanged drug.
Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for minimal clearance.
Category C
Category C
Corticosteroid
Corticosteroid